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Abstract 
Background: Enteric and diarrheal diseases are important causes of childhood death in the developing world. These 
diseases are responsible for more than 750 thousand deaths in children under 5 years old worldwide, ranking second 
cause of death, after lower respiratory diseases, in this age group. Among the major causative agents of diarrhea is 
Escherichia coli. There are several vaccine trials for diarrheagenic E. coli. However, diarrheagenic E. coli has seven patho-
types and vaccines are directed for one or two of the five main pathotypes-causing diarrhea. Currently, there are no 
combined vaccines available in the market for all five diarrheagenic E. coli pathotypes. Therefore, we aimed to develop 
a low-cost vaccine candidate combining the five main diarrheagenic E. coli to offer wide-spectrum protection. We 
formulated a formalin-killed whole-cell mixture of enteroaggregative, enteropathogenic, enteroinvasive, enterohem-
orrhagic, and enterotoxigenic E. coli pathotypes as a combined vaccine candidate.
Results: We immunized Balb/C mice subcutaneously with 109 CFU of combined vaccine candidate and found a sig-
nificant increase in survival rate post challenge compared to unimmunized controls (100 % survival). Next we aimed 
to determine the immunological response of mice to the combined vaccine candidate compared to each pathotype 
immunization. To do so, we immunized mice groups with combined vaccine candidate and monitored biomarkers 
levels over 6 weeks as well as measured responses post challenge with relevant living E. coli. We found significant 
increase in specific systemic antibodies (IgG), interferon gamma (IFNγ) and interleukin 6 (IL-6) levels elicited by com-
bined vaccine candidate especially in the first 2 weeks after mice immunization compared to controls (p < 0.05). We 
also evaluated alum and cholera toxin B subunit (CTB) as potential adjuvant systems for our candidate vaccine. We 
found that CTB-adjuvanted combined vaccine candidate showed significantly higher IgG and IFNγ levels than alum.
Conclusions: Overall, our combined vaccine candidate offered protection against the five main diarrheagenic E. coli 
pathotypes in a single vaccine using mouse model. To the best of our knowledge, this is the first combined vaccine 
against the five main diarrheagenic E. coli pathotypes that is cost-effective with promise for further testing in humans.
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Background
Diarrhea is a major public health problem that usu-
ally lasts a day or two and often disappears without any 
special treatment. However, prolonged diarrhea can 
cause severe dehydration and even death [1]. One of the 
causative agents of diarrhea is Escherichia coli. There are 
several pathotypes of E. coli that cause infections of the 
gastrointestinal system while other pathotypes cause 
infections outside the gastrointestinal system as bactere-
mia, nosocomial pneumonia and neonatal meningitis [2].
Diarrheagenic E. coli can be categorized into subgroups 
including enterotoxigenic E. coli (ETEC) that affects small 
intestine [2, 3]. ETEC is a major cause of traveler diarrhea 
and is responsible for 280 million diarrheal episodes and 
more than 400 thousand death annually [1]. Enteropatho-
genic E. coli (EPEC) affects small intestine and is respon-
sible for infant diarrhea with fever, nausea and vomiting. 
Enterohaemorrhagic E. coli (EHEC) affects large intestine 
and leads to severe abdominal pain, watery diarrhea fol-
lowed by bloody diarrhea leading to hemolytic uremic 
syndrome [2, 3]. Enteroinvasive E. coli (EIEC) affects 
large intestine and produce shigella-like diarrhea and is 
responsible for tissue invasion and destruction of epithe-
lial cells [2, 3]. The fifth and final subgroup is enteroag-
gregative E. coli (EAEC), which affects small intestine 
and is responsible for endemic diarrhea of infants in both 
industrialized and developing countries [4, 5].
In diseases caused by E. coli, current treatments do not 
cure the infection, but are directed to relieve symptoms 
or prevent complications. Treatment includes rest and 
fluids administration to help prevent dehydration and 
fatigue. Currently researchers are investigating potential 
vaccines to reduce the chance of exposure to E. coli [6]. 
There are several types of vaccines including inactivated 
vaccines that require several additional doses or booster 
shots, live attenuated, subunit, toxoid, conjugate, DNA 
and recombinant vector vaccines [7, 8]. The development 
of vaccines against diarrheagenic E. coli pathotypes rep-
resents a major challenge because of the large number of 
serotypes involved and the requirement to induce immu-
nity that is effective in the gut [9, 10].
In addition, inclusion of an immunological agent that 
modifies the immune response of vaccine and produce 
long lasting immunity is needed. These adjuvants mini-
mize the amount of injected foreign material. Some 
adjuvants, such as alum are approved for human use 
worldwide with few exceptions. The adjuvant activity 
of aluminum compounds was demonstrated since 1926 
with diphtheria toxoid adsorbed on alum [11]. Reports 
have also demonstrated that alum has limitations espe-
cially when several doses are recommended [12], so there 
is a need for novel model of adjuvants to be designed. 
Cholera toxin (CT) is a potent oral and parenteral 
immunogen, however, the toxicity associated with CT 
makes it an unlikely candidate for human use. The chol-
era toxin B subunit (CTB) has been used instead of chol-
era toxin as an adjuvant as B–subunit lacks toxicity, has 
potent biological properties and is a powerful mucosal 
and parenteral adjuvant that induces a strong immune 
response against co-administered or coupled antigens 
[13]. Another difference between CT and CTB is that CT 
induces the release of inflammatory cytokines such as 
IL-6 and IL-1β, while the reverse is true with CTB that 
inhibit IL-6 release [14].
The present work aimed to develop combined inacti-
vated vaccine candidates of five subgroups of diarrhea-
genic E.coli to provide wide protection against different 
pathotypesof E. coli. In addition, we compared the poten-
tials of alum and cholera toxin B subunit as adjuvants 
in augmenting humoral immune response to candidate 
E. coli vaccine. The results showed that candidate com-
bined vaccine was safe and effective in protection against 
living E. coli. Thus giving promising results in stimulat-
ing humoral immune responses in mouse model. We 
also found that CTB elicited a significant increase in the 
immune response as compared with alum, suggesting 
better response as adjuvant.
Results
Mice immunized with combined candidate E. coli vaccine 
exhibited 100 % survival when challenged with living  
E. coli
We evaluated the immune efficacy of adjuvanted and 
unadjuvanted formalin-killed whole-cell combined E. 
coli vaccine candidate by comparing survival of pre-
immunized mice following challenge with living E. coli. 
We immunized twice Balb/C mice (n  =  5 mice/group) 
subcutaneously with 109 CFUs of unadjuvanted, alum-
adjuvanted or CTB-adjuvanted formalin-killed whole-
cell vaccine candidates. Combined vaccine candidate 
consisted of the five main pathotypes of diarrheagenic 
E. coli we formulated. We also immunized mice using 
the five different individual E. coli pathotypes, EAEC, 
EPEC, EIEC, EHEC, and ETEC. Formalin served as vehi-
cle controlin addition to PBS control group, for a total of 
20 groups (n = 5 mice per group) (Table 1). Two weeks 
after immunization, mice groups were challenged intra-
peritoneally with 106 CFU of respective living E. coli 
pathotypesor combination of the five E. colipathotypes.
We found that the combined vaccine candidate whether 
adjuvanted or not showed 100 % survival rate post chal-
lenge compared to unimmunized controls (p  <  0.0001) 
(Fig. 1). Similar responses were observed with 100 % sur-
vival ratein mice immunized with each CTB- adjuvanted 
E. coli pathotypes (Fig.  1c). However, survival rate of 
mice immunized with unadjuvanted or alum-adjuvanted 
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individual E. coli pathotypes ranged between 50 and 
100 % depending on the adjuvant (Fig. 1).
Survival rates were different depending on adjuvant 
(Fig.  1) therefore we analyzed the effect of adjuvantson 
mice survival rate post challenge. We found that CTB 
showed 100  % survival compared to alum and unadju-
vanted vaccine candidates (Fig. 2). For each vaccine can-
didate, we compared survival rates of unadjuvanted, CTB 
and alum-adjuvanted candidates. We found that there 
was no difference in survival of mice immunized with 
either unadjuvanted, CTB or alum adjuvanted combined 
vaccine candidate, with 100  % survival (Fig.  2a). Simi-
larly, different adjuvant systems showed similar survival 
rates (100 %) in mice immunized with individual EAEC 
and EPEC pathotypes (Fig. 2b, c). However, mice immu-
nized with CTB-adjuvanted EHEC and ETECpathotypes 
showed higher survival rates than alum and non-adju-
vanted vaccines (Fig. 2e, f ). Both adjuvant systems used 
offered better protection than unadjuvanted EIEC 
(Fig. 2d). In general, combined vaccine candidate showed 
100  % survival rate irrelevant of adjuvant system used, 
offering protection from all five main pathotypesof diar-
rheagenic E. coli in a single dose.
We also immunized Balb/c mice using oral gavage 
with ~2  ×  109 CFU of combined vaccine. Two control 
groups received sodium bicarbonate vehicle and forma-
lin orally. One week later, we challenged the mice with 
~2 ×  108 CFU of living combined E. coli by oral route. 
We observed mice groups daily for 1 week post challenge 
and found that immunized mice did not develop diarrhea 
and survived challenge compared to controls (p < 0.0001) 
(Additional file 1: Figure S1).
Candidate vaccine elicits specific systemic antibodies 
in sera of immunized mice
With 100 % survival post challenge of immunized mice, 
we aimed to assess in  vivo specific humoral immune 
responses. We used mouse model immunized subcu-
taneously with 109 CFU of respective formalin-killed 
whole-cell diarrheagenic E. coli. Mice (n = 10 per group) 
were then challenged intraperitoneally with 106 CFU of 
respective living diarrheagenic E. coli. Post-challenge 
specific IgG absorbance values against respective E. coli 
antigens were significantly higher in mice immunized 
with combined vaccine candidate than those immu-
nized with individual E. coli pathotypes (p < 0.05) (Fig. 3, 
Additional file 2: Figure S2 and Additional file 3: Figure 
S3). An exception was mice immunized with EIEC alum 
adjuvanted and ETEC non-adjuvanted although showed 
higher IgG absorbance values; however did not reach sig-
nificance (Additional file 2: Figure S2C and 2E).
We also monitored specific IgG antibody response over 
6  weeks period post immunization with respective for-
malin-killed whole-cell vaccine. We selected time points 
7, 14, 21, 28, 42 days to evaluate sustainability of immune 
response elicited by different diarrheagenic E. coli patho-
types in comparison to combined vaccine candidate. We 
found a general pattern of increase in specific IgG absorb-
ance values compared to individual E. coli pathotypes at 
most time points (p < 0.05) (Fig. 3; Additional file 2: Figure 
Table 1 E. coli pathotypes and  mouse immunization and   
challenge groups used in the study
Immunization antigen (s) (whole-cell 
formalin-treated)
Challenge E. coli antigen 
(s) (live whole-cell)
Unadjuvanted, alum or CTB-adujvanted
 Enteroaggregative E. coli (EAEC) (RKI 17-2) EAEC
 Enteroinvasive E. coli (EIEC) ATCC 
43893  (O124: NM)
EIEC
 Enterohaemorrhagic E. coli (EHEC) 
ATCC  43890 (O157:H7)
EHEC
 Enteropathogenic E. coli (EPEC) [50, 51] EPEC
 Enterotoxigenic E. coli (ETEC) [50, 51] ETEC
 Combined antigens cocktail: EAEC, 
EPEC,  EIEC, EHEC, ETEC
Combined cocktail
Controls
 Formalin Combined cocktail






(See figure on next page.) 
Fig. 1 Comparative evaluation of mice survival post immunization with combined vaccine candidate versus independent individual E. coli anti-
gens. Balb/C mice (n = 5 mice/group) were double immunized subcutaneously with 109 CFU of formalin killed whole cell E. coli antigens. Antigens 
belonged to the main diarrheagenic E. coli pathotypes, Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC), Enteroinvasive E.coli (EIEC), 
Enterohaemorrhagic (EHEC) or Enterotoxigenic (ETEC). Combined vaccine consisted of the main five pathotypes EAEC, EPEC, EIEC, EHEC and ETEC. 
Two weeks later, mice were challenged intraperitoneally with 106 CFU of respective living E. colipathotype. Survivalcurves of mice groups post 
immunization with a unadjuvanted combined vaccine candidaterelative to unadjuvanted individual E. coli antigenswithvehicle (formalin) and PBS 
as controls. b Alum adjuvanted combined vaccine candidate relative to the alum adjuvanted individual antigens and controls. c CTB-adjuvanted 
combined vaccine candidate relative to the CTB-adjuvanted individual antigens using appropriate controls. p < 0.0001 comparing immunized 
groups to formalin and PBS controls
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S2 and Additional file 3: Figure S3). Details of exceptions 
to the pattern were mice immunized with CTB-adju-
vanted EAEC showed comparable IgG absorbance values 
to combined vaccine at all time points prior to challenge 
(Fig.  3a). Mice immunized with alum-adjuvanted 
EAEC showed comparable absorbance values of IgG to 
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Fig. 2 Evaluation of the effect of adjuvant system on survival rate in mice immunized with combined or individual antigens. Balb/C mice were 
double immunized subcutaneously with 109 CFU of formalin killed whole cell antigens. Antigens belonged to the above-mentioned five-diarrhe-
agenic E. coli pathotypes. Combined vaccine candidate consisted of formalin-killed whole cells of the main five pathotypes. Two weeks later, mice 
were challenged intraperitoneally with 106 CFU of respective living E. colipathotype. Evaluation of the effect of adjuvant system on the survival rate 
of mice groups post immunization with a combined vaccine candidate, b EAEC antigens, c EPEC antigens, d EIEC antigens, e EHEC antigens, and f 
EHEC antigens. In each group, appropriate controls were used. p < 0.05 were considered statistically significant when comparing immunized groups 
to formalin and PBS controls
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combined vaccine candidate at 21, 28 and 42 days prior to 
challenge (Additional file2: Figure S2A) and those immu-
nized with unadjuvanted EAEC had similar absorbance 
values to the combined candidate at 21 and 28 days post 
immunization (Additional file  3: Figure S3A). Another 
exception was EPEC unadjuvanted and alum adjuvanted 
showed comparable absorbance values of IgG to the com-
bined vaccine at some of the time points measured (Addi-
tional file 2: Figure S2B and Additional file 3: Figure S3B). 
EIEC, EHEC and ETEC alum adjuvanted antigens showed 
comparable IgG absorbance values to combined vaccine 
candidate at 21, 28 and 42  h post immunization (Addi-
tional file  2: Figure S2C). In general, CTB-adjuvanted 
combined vaccine candidates elicited significantly higher 
sustained specific immunoglobulin absorbance values 
over 6 weeks than individual E. coli antigens.
CTB-adjuvanted candidate vaccine elicits highest response 
of specific antibodies in sera of immunized mice
To analyze adjuvant system immune efficacy in our com-
bined candidate vaccine for diarrheagenic, we compared 
the effects of CTB and alum on absorbance values of IgG 
post immunization with formalin-killed whole-cell E. coli 
in Balb/C mouse model. We immunized mice with for-
malin-killed whole-cell E. coli pathotypes and combined 
vaccine (109 CFU). We monitored serum absorbance val-
ues of IgG every week for 6 weeks post immunization. At 
week 7, we challenged mice with respective living E. coli 
pathotype (106 CFU) and measured specific IgG absorb-
ance values post challenge. We found in general that CTB 
elicited significantly higher sustained immune response 
over 6  weeks after immunization. When the mice were 
challenged with the living strains, we found increase in the 
immune response than before challenge with the different 
pathotypes. CTB achieved overall higher significance than 
alum and unadjuvanted vaccine candidate post challenge, 
but elicited comparable immune response against alum 
with combined candidate, EIEC and ETEC (Fig. 4a, d, f ).
Candidate vaccine stimulates pro-inflammatory cytokines 
production in sera of immunized mice
We analyzed selected pro-inflammatory cytokines lev-
els in sera of mice immunized with each pathotype and 
the combined five pathotypes, whether adjuvanted with 
CTB or alum. We found that in general, adjuvanted anti-
gens elicit higher levels of the measured pro-inflamma-
tory cytokines (Figs.  5 and 6). IFNγ sera levels in mice 
immunized with CTB-adjuvanted antigens were sig-
nificantly higher than alum-adjuvanted antigens (Fig. 6). 
Meanwhile,IL-6 levels elicited by CTB-adjuvanted anti-
gens were as low as diluent assay and lower than either 
unadjuvanted or alum-adjuvanted antigens. This is due to 
inhibitory effect of CTB on IL-6 production reported in 
several mice models [14–16]. Meanwhile, IL-6 levels elic-
ited by candidate vaccine whether unadjuvanted or alum-
adjuvanted were significantly higher than the each E. coli 
pathotype (Fig.  7 and Additional file  4: Figure S4). This 
is especially true during the first 2 weeks after immuni-
zation and post challenge except for ETEC (Fig. 7f ). We 
also found that serum levels of pro-inflammatory IFNγ 
in mice immunized with either non-adjuvanted, CTB or 
alum adjuvanted were significantly higher in response 
to combined antigens than individual antigens (p < 0.05, 
0.001 and 0.0001) (Fig. 8, Additional file5: Figure S5, and 
Additional file 6: Figure S6).
Discussion
Enteric and diarrheal diseases are a major cause of child-
hood death in the developing world, ranking second 
cause of death in children under 5  years old [17]. Due 
to high mortality, several international organizations 
such as WHO and UNICEF have dedicated preventive 
and control programs for diarrheal diseases. Prevention 
methods include vaccines and improvement in water 
supplies, hygiene and sanitation. Among the leading 
causes of diarrhea is E. coli. Infection with various patho-
types of E. coli causes a high percentage of death in chil-
dren under 5  years old in the developing world. ETEC 
diarrheal infection alone is responsible for 1.3 million-
death cases annually [18].
There have been successful trials for development of 
vaccines to individual pathotypes of E. coli; these vaccine 
candidates are reviewed in [19–21]. Despite these success-
ful vaccine trials, there is no single vaccine available for all 
the different types of E. coli causing diarrhea. Combina-
tion vaccines have several advantages including reducing 
(See figure on previous page.) 
Fig. 3 Evaluation of in vivo specific IgG antibody response measured as absorbance values elicited by CTB-adjuvanted combined vaccine candi-
date. Balb/C mice (n = 10 mice per group) were immunized subcutaneously with 109 CFU of formalin killed whole cell antigens. Antigens belonged 
to the above-mentioned five-diarrheagenic E. coli pathotypes,. Combined vaccine candidate consisted of formalin-killed whole cell of the main five 
pathotypes. Post-immunization blood samples were collected from mice groups weekly for 6 weeks. At week seven, mice were challenged with 
106 CFU intraperitoneally and blood samples were collected 1 week after the challenge. Absorbance values of specific IgG antibody was meas-
ured for all seven intervals. Antibody absorbance values of combined vaccine candidate at selected time points compared to a EAEC antigens, b 
EPEC antigens, c EIEC antigens, d EHEC antigens and ETEC antigens. *p < 0.05, ** p < 0.001, ***p < 0.0001, and ****p < 0.00001, each bar represents 
mean ± standard deviation
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Fig. 4 Effect of adjuvant system on antibody response measured as absorbance values of combined vaccine candidate. Balb/C mice (n = 10 
mice per group) were immunized subcutaneously with 109 CFU of formalin killed whole cell antigens. We used antigens of the above-mentioned 
five-diarrheagenic E. coli pathotypes. Combined vaccine candidate consisted of formalin-killed whole cell antigens of the main five pathotypes. The 
absorbance values of antibodies were monitored at these intervals. Bar chart of antibody absorbance values after mice immunization with adjuvant 
systems with a combined vaccine candidate. b EAEC antigens. c EPEC antigens. d EIEC antigens. e EHEC antigens. f ETEC antigens using appropri-
ate controls. *p < 0.05, ** p < 0.001, ***p < 0.0001, and ****p < 0.00001, each bar represents mean ± standard deviation
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Fig. 5 Effect of adjuvant system onIL-6 levels of combined and individual antigens. Balb/C mice (n = 10 mice per group) were immunized sub-
cutaneously with 109 CFU of formalin killed whole cell antigens. We used antigens of the above-mentioned five-diarrheagenic E. coli pathotypes. 
Combined vaccine candidate consisted of formalin-killed whole cell antigens of the main five pathotypes. The concentrations of interleukin 6 were 
monitored at these intervals. Bar chart of interleukin 6 levels after mice immunization with adjuvant systems with a combined vaccine candidate. 
b EAEC antigens. c EPEC antigens. d EIEC antigens. e EHEC antigens. f ETEC antigens using assay diluents as a control. *p < 0.05, ** p < 0.001, and 
***p < 0.0001, and ****p < 0.00001 each bar represents mean ± standard deviation
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Fig. 6 Effect of adjuvant system on IFNγ levels. Balb/C mice (n = 10 mice per group) were immunized subcutaneously with 109 CFU of formalin 
killed whole cell antigens. We used antigens of the above-mentioned five-diarrheagenic E. coli pathotypes. Combined vaccine candidate consisted 
of formalin-killed whole cell antigens of the main five pathotypes. The concentrations of IFNγ were monitored at these intervals. Bar chart of IFNγ 
levels after mice immunization with adjuvant systems with a combined vaccine candidate. b EAEC antigens. c EPEC antigens. d EIEC antigens. e 
EHEC antigens. f ETEC antigens using assay diluents as a control. *p < 0.05, ** p < 0.001, and ***p < 0.0001, and each bar represents mean ± stand-
ard deviation
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Fig. 7 Evaluation of IL-6 levels elicited by combined vaccine candidate. Balb/C mice (n = 10 mice per group) were immunized subcutaneously 
with 109 CFU of formalin killed whole cell antigens. Antigens belonged to the above-mentioned five-diarrheagenic E. coli pathotypes. Combined 
vaccine candidate consisted of formalin-killed whole cell of the main five pathotypes. Post-immunization blood samples were collected from mice 
groups weekly for 6 weeks. At week seven, mice were challenged with 106 CFU intraperitoneally and blood samples were collected 1 week after the 
challenge. The concentration of IL-6 was measured for all seven intervals. IL-6 concentration of combined vaccine candidate at selected time points 
compared to a EAEC antigens, b EPEC antigens, c EIEC antigens, d EHEC antigens and e ETEC antigens. p < 0.05, ** p < 0.001, ***p < 0.0001, and, 
each bar represents mean ± standard deviation
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Fig. 8 Evaluation of IFNγ levels elicited by combined vaccine candidate. Balb/C mice (n = 10 mice per group) were immunized subcutaneously 
with 109 CFU of formalin killed whole cell antigens. Antigens belonged to the above-mentioned five-diarrheagenic E. coli pathotypes. Combined 
vaccine candidate consisted of formalin-killed whole cell of the main five pathotypes. Post-immunization blood samples were collected from mice 
groups weekly for 6 weeks. At week seven, mice were challenged with 106 CFU intraperitoneally and blood samples were collected 1 week after the 
challenge. The concentration of IFNγ was measured for all seven intervals. IFNγ concentration of CTB-adjuvanted combined vaccine candidate at 
selected time points compared to a EAEC antigens, b EPEC antigens, c EIEC antigens, d EHEC antigens and e ETEC antigens. *p < 0.05, ** p < 0.001, 
and ***p < 0.0001, each bar represents mean ± standard deviation
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the cost of manufacturing separate vaccines and extra 
health care visits. Having one combined vaccine improves 
timeliness of vaccination as some parents and health care 
providers raised objections to administering multiple 
injections during a single visit. This is considered a major 
advantage of combined vaccines [22]. Several combina-
tion vaccines have achieved great success in immunization 
as MMR and DTP, encouraging formulating combina-
tion vaccine for E. coli. Dukoral is an example of success-
ful combined whole cell killed cholera vaccine available in 
market. It consists of mixture of four preparation of whole 
cell inactivated Vibrio cholera O1 (Inaba and Ogawa sero-
types, classical and El Tor biotypes) with recombinant 
CTB [23]. We took into consideration the advantages of 
combined vaccines and designed our candidate-combined 
vaccine of different diarrheagenic E. coli pathotypes. Our 
candidate vaccine induced humoral immune response 
at measured time points offering protection against diar-
rhea in tested murine model. Mice immunized with our 
candidate combined diarrheagenic E. coli vaccine showed 
marked survival rate post challenge compared to control 
groups. In addition, high specific antibodies responses to 
each antigen were elicited post immunization of mice and 
at selected time points and post challenge.
There is a possible relationship between the mainte-
nance of specific antibody response post immunization 
with inactivated whole-cell E. coli mixture and B cell 
mediated memory response to challenge with living bac-
teria [21, 24]. This is evident in our study where, stimu-
lation of the immune response via immunization with 
combined vaccine containing inactivated whole-cells of 
the five main E. coli pathotypes led to production of spe-
cific IgG in immunized mice. This specific IgG response 
was sustained over the period of 6 weeks post immuni-
zation (Fig.  4). Due to specific B-cell memory immune 
responses, this specific IgG was significantly high post 
challenge. Specific IgG response in combination with 
production of IFNγ conferred protection from diarrhea 
(Figs.  4, 6, 8). Thus resulting in significantly higher sur-
vival (100  %) of the immunized mice compared to con-
trols (P  <  0.005) (Fig.  2). Adjuvant systems used in this 
study, alum and CTB, have potentiated action of the anti-
gen. Due to variations in adjuvant nature of alum and 
CTB, where CTB in itself is immunogenic, thus induced 
higher immune response than alum post immunization. 
In addition, CTB maintained a good level of specific anti-
bodies than alum (Fig.  4). Mean while, post challenge, 
there was no significant difference between CTB and 
alum as adjuvant systems in the specific IgG response 
except in EHEC, EAEC and EPEC where CTB induced 
the highest response (Fig.  4). This might be due to the 
excellent adjuvant effect of both CTB and alum, however 
the exact reason might need further investigation.
We also demonstrated that there was a significant 
increase in relevant cytokines levels post immunization. 
These are important features to any effective vaccine can-
didate where specific response was attained. Develop-
ments of vaccines against various pathotypes of E. coli 
using animal models have usually used specific subunits, 
toxins, secreted, or recombinant proteins offering sig-
nificant protection [25–30]. The use of specific subunits, 
toxins or recombinant proteins offers significant protec-
tion and has been critical in recent advances in vaccines 
development. However, we chose to use whole–cell vac-
cine due to several reasons. One of these reasons is that 
preparation of whole-cell vaccines is easy and of low-
cost, making such a vaccine cost-effective and very use-
ful for poor countries where diarrhea is a critical health 
problem among infants and children [31, 32]. Addition-
ally, oral ETEC whole-cell vaccines have been proven safe 
and effective in immunizing infants and children in clini-
cal trials. In addition, oral whole-cell typhoid vaccine, 
Ty2a, has proved to be effective, safe and immunogenic 
offering protection from typhoid. Moreover, we aimed to 
offer wide-protection by combining major pathotypes of 
diarrheagenic E. coli and having all antigens of a whole-
cell vaccine. Thus, our candidate combined vaccine is 
simple to prepare in addition it offers both efficacy and 
cost-effectiveness.
Dosing is another important consideration when for-
mulating E. coli vaccines. Usually several doses are 
needed to maintain an efficient immunity. This would be 
an economical burden for developing countries where 
diarrhea caused by E. coli is prevalent. To overcome this 
limitation, vaccines are formulated with adjuvants that 
stimulate the immune response at either the cellular or 
humoral level and generate a depot effect, by stimulating 
a granuloma around the antigen. However, the choice of 
an appropriate adjuvant requires careful considerations 
[33]. One of the commonly used adjuvants in human vac-
cination is alum. Alum is found in numerous vaccines, 
including diphtheria-tetanus-pertussis, human papil-
lomavirus and hepatitis vaccines [34]. Alum provokes a 
strong Th2 response, but it is rather ineffective against 
pathogens that require Th1–cell-mediated immunity 
[35]. However, alum has several side effects when high 
doses of vaccines are required. High levels of alum in the 
body affect multiple organs causing brain and bone tis-
sue damage leading to fatal neurological syndrome [35]. 
Another commonly used adjuvant is cholera toxin (CT). 
CT has immune modulatory effects on different cell 
types; the interaction of CT with dendritic cells may be 
critical for its adjuvant activity [36, 37]. In addition, CT 
augments cellular immune responses of co-administrated 
antigens eliciting the production of IL-4, IL-5 and IL-10 
[38]. B-subunits of CT are the commonly used form of 
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CT in enhancing the immune response to conjugated 
antigens [38–44]. All these immunogenic effects of adju-
vants make their choice an important consideration in 
vaccine development. Therefore, another aim of our 
work was to study the effect of adjuvants on the immune 
response of whole cell formalin killed diarrheagenic.
Our results showed a significant increase in the 
immune responses associated with the whole cell forma-
lin inactivated E. coli combined with cholera toxin B sub-
unit than that achieved with alum. IFNγ levels increased 
after immunization whether using CTB or alum in agree-
ment with previous studies [45, 46]. However, we found 
that CTB-adjuvanted vaccine candidates elicited a sig-
nificant increase in IFNγ level than that detected with 
alum. The reverse was observed withIL-6, where alum 
increased the concentration of IL-6, but CTB did not 
affect its secretion in agreement with [14–16]. This is 
due to possible inhibitory effects of CTB on both B cell 
dependent and independent pathways for IL-6 produc-
tion [15, 16].
Survival rate after mice challenge is used to evaluate 
the efficacy and safety of the formulated vaccine candi-
dates. Our results showed that the survival rate after 
immunization with vaccine candidate whether non-adju-
vanted or adjuvanted was significantly higher than the 
controls. However, on comparing selected adjuvants, we 
found that survival rate post immunization with CTB-
adjuvanted vaccine was higher than alum. Collectively, 
our results suggested that CTB-adjuvanted combined 
vaccine had more advantages than alum adjuvanted as far 
as protection, eliciting immune responses and survival 
rates.
Finally, we aimed to assess involvement of immune cell 
populations in protection, we analyzed cell populations 
post immunization and challenge in mice groups. Dif-
ferent E. coli pathotypes have been reported to induce 
mucosal inflammatory responses with infiltration of 
neutrophils to site of infection [47–49]. However, in our 
model of combined vaccine candidate, we found that 
NLR (neutrophil lymphocyte ratio) did not significantly 
differ from the controls and this is in agreement with 
[50] where killed bacterial vaccines usually do not elicit 
migration of neutrophils.
Conclusions
We developed and tested a new combined vaccine in 
mice, alone and with an adjuvant system. The vaccine 
contained E. coli main five diarrheagenic pathotypes 
ETEC, EHEC, EIEC, EAEC and EPEC. Immunization of 
mice induced serum antibody responses to all antigens in 
the combined vaccine. In addition, immunized mice had 
protective pro-inflammatory responses and higher sur-
vival rates post challenge. These responses were further 
enhanced by adjuvant systems whether alum or CTB. 
We found that CTB was a better adjuvant to our vaccine 
candidate than alum. The vaccine, both with and without 
adjuvants, was stable and well tolerated. Our ongoing 
studies focuses on formulating our candidate vaccine as 
oral instead of subcutaneous vaccine. A change in route 
of vaccine administration is anticipated to be successful 
as there have been several oral vaccine trials that proved 
safe and immunogenic using various E. coli diarrhea-
genic pathotypes, for example ETEC/rCTB [31, 32]. Our 
candidate vaccine offers protection against the five main 
diarrheagenic E. coli in a single dose. However, vaccina-
tion might affect gut flora in human beings and it would 
be interesting to see if our candidate combined vaccine 
might affect gut microbiota prior to clinical trials. In 
addition, further studies on extended immunity and clini-
cal studies in humans would be valuable.
Methods
Bacterial strains and culturing conditions
We used standard reference strains of Enteroaggregative 
E.coli (EAEC) (RKI 17-2), Enteroinvasive E. coli (EIEC) 
ATCC 43893 (O124:NM, USA), and Enterohaemorrhagic 
E. coli (EHEC) ATCC 43890 (O157:H7). In addition, 
reference strains of Enterotoxigenic E. coli (ETEC) and 
Enteropathogenic E. coli (EPEC) were kindly provided by 
Dr. Marwa E.A. Aly [51, 52].
Escherichia coli were cultured in Luria Broth (LB) 
(Difco, Sparks, MD, USA) at 37°c for 14  h and har-
vested with phosphate buffer saline (PBS) (Bio Basic Inc., 
Ontario, Canada). Cells were washed in PBS by centrifu-
gation at 500×g for 10 min at 4°c [53]. The concentration 
of E. coli was adjusted at 109 CFU/ml. Formalin (Fischer-
scientific, Leicestershire, UK) was then added (0.4 %) to 
kill E. coli. The formalin treated bacteria was kept for 24 h 
to ensure killing action of the formalin. Formalin-treated 
bacterial suspensions were confirmed dead as there was 
no living microorganisms found on inoculating the sus-
pensions in LB. The killed organisms were harvested by 
centrifugation at 6000×g for 1 h at 4°c then washed twice 
with sterile PBS (pH 7.2). The pellets obtained were re-
suspended in PBS. We performed sterility testing of pre-
pared formalin inactivated vaccine to check if there was 
contamination by other bacteria. Sterility test was done 
by taking a loop full of the prepared formalin killed anti-
gen onto blood agar, McConkey agar plates and thiogly-
collate broth (Sigma Aldrich, Saint Louis, MO, USA) and 
incubating for 24–48 h at 37° [54].
Adjuvants preparation
We prepared Aluminum phosphate (alum) (Sigma 
Aldrich, Saint Louis, MO, USA) by preparing 0.63  M 
AlCl3.6H2O and sodium phosphate solution(0.3  M 
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Na3PO4.12 H2O)each in 40 ml saline and sterilized by fil-
tration. Final alum adjuvant was prepared according to 
the method detailed in [12, 55, 56]. Recombinant CTB 
(rCTB) was kindly provided from the Holding Company 
for Biological Products and Vaccines (VACSERA, Giza, 
Egypt).
Animals
Balb/C male and female mice, 6–8 weeks old were used 
for all experiments. The mice were purchased from VAC-
SERA to Helwan (VACSERA vivarium, Helwan, Egypt). 
Animals were housed in accordance with standard labo-
ratory conditions with access to food and water ad  libi-
tum, in an environmentally controlled room with 12  h 
light and dark cycles. A total of 325 mice were used in 
this study to determine effect of combined candidate 
vaccine on survival post-challenge and immunological 
response of mice to the candidate vaccine.
All animal experiments were conducted in accordance 
with the institutional regulations. The Institutional Ethi-
cal Committee of the Faculty of Pharmacy, Cairo Univer-
sity, Egypt, approved animal studies (approved protocol 
number MI (737)).
Mice immunizations
Balb/C mice (n = 5 mice/group, for a total of 125 mice) 
were double immunized one-week apart subcutaneously 
with 109 CFU of respective unadjuvanted, alum–adju-
vanted or CTB-adjuvanted formalin–killed whole–cell 
combined vaccine candidate (Table  1). We also immu-
nized the mice with each of the five main diarrheagenic 
E. coli pathotypes, EAEC, EPEC, EIEC, EHEC, and 
ETEC. Formalin served as vehicle control in addition 
to PBS control group, for a total of 25 groups (Table 1). 
After 2 weeks the mice were injected the challenge dose 
106 CFU (0.5 ml) of respective E. coli pathotype intraperi-
toneally and the mice were observed for 7 days and the 
rate of survival was determined [57].We tested our candi-
date vaccine using oral route by immunizing Balb/c mice 
by oral gavage with ~2 × 109 CFU of combined vaccine 
in 300 μl of sodium bicarbonate twice 1 week apart. Two 
control groups received orally 300 μl of sodium bicarbo-
nate vehicle and formalin. We observed mice daily for 
1 week then the mice were challenged with ~2 × 108 CFU 
of living combined E. coli pathotypes by oral route. We 
observed mice groups daily for 1-week post challenge.
Assessment of immunological response patterns of the 
candidate vaccine
We immunized Balb/C mice (n = 10 per group) subcu-
taneously with 109 CFU of respective formalin-killed 
whole-cell diarrheagenic E. coli pathotypes (Table  2). 
We collected blood from mice to monitor the immune 
responses weekly for 6 weeks. At week 7, mice were then 
challenged intraperitoneally with 106 CFU of respective 
living diarrheagenic E. coli pathotype and monitored for 
one-week post challenge. Control groups included CTB, 
alum, formalin and PBS (n = 5 per control group), for a 
total of 200 mice used in immunological response assess-
ment experiments. All control groups were challenged 
with combined candidate vaccine (Table 2).
Detection of antibodies against E. coli antigen
We collected blood samples weekly throughout the 
experiment via retro-orbital plexus of immunized mice 
groups (Table  2). Sera were collected by cold centrifu-
gation for 15  min at 5000  rpm. Enzyme Linked Immu-
nosorbent assay (ELISA) plates (Nunc-Denmark) were 
coated with whole-cell inactivated E. coli antigen in 
carbonate-bicarbonate buffer (Sigma Aldrich, Saint 
Louis, MO, USA), pH 9.6 as 100  µl/well(6  µg/ml) and 
the experiment was processed according to established 
previous studies [58–60]. Sera from two mice per group 
were pooled and assessed for a total of five mice pools 
per group.
Cytokines assays
We measured levels of pro-inflammatory cytokines in 
sera of mice groups (Table 2).We pooled sera of five mice 
per group prior to assay and assessed levels of IL-6 and 
IFNγ using ELISA method according to the manufac-
turer’s protocol (BiooScientific Co., Austin, TX, USA). 
Concentrations were calculated based on standard curve 
analysis (Additional file 7: Figure S7).
Complete blood count analysis
We collected blood from mice in EDTA-coated tubes 
and analyzed percentages of neutrophils and lymphocyte 
Table 2 Groups of mice used in assessment of immunolog-
ical response to candidate vaccine
Immunization antigen Challenge E. coli pathotype
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using slide method. We calculated neutrophils lympho-
cyte ratio. All samples were compared to the control 
groups.
Statistical analysis
Data were analyzed using GraphPad Prism 6.01 (Graph-
Pad Software Inc., California, USA). We used analysis 
of variance (one way analysis of variance (ANOVA)) for 
comparison of cytokine and antibody levels means. Sta-
tistical analyses for comparison of antibody absorbance 
values or cytokine levels elicited by combined candidate 
vaccine and each of E. coli antigens was calculated using 
unpaired Student’s t-test. Significance testing for compar-
ison of survival curves was done using Log-rank (Mantel- 
Cox)test. p less than 0.05 were considered significant.
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Additional files
Additional file 1: Figure S1. Comparative evaluation of mice survival 
post immunization with combined vaccine candidate versus controls. 
Balb/C mice (n = 5 mice/group) were immunized twice (a week apart) by 
oral route with 109 CFU of formalin killed whole cell combined candidate 
of diarrheagenic E. coli. Combined vaccine consisted of the above-
mentioned five-diarrheagenic E. coli pathotypes. Two weeks later, mice 
were challenged orally with 108 CFU of live combination of diarrheagenic 
E. coli pathotypes. Survival curves of mice groups post immunization 
with unadjuvanted combined vaccine candidate relative to formalin and 
sodium bicarbonate controls. p < 0.05 was considered significant, **** 
p < 0.0001 comparing immunized groups to formalin and sodium carbon-
ate controls.
Additional file 2: Figure S2. Evaluation of in vivo specific IgG antibody 
response measured as absorbance values elicited by alum adjuvanted 
combined vaccine candidate. Balb/C mice (n = 10 mice per group) were 
immunized subcutaneously with 109 CFU of formalin killed whole cell 
antigens. Antigens belonged to the above-mentioned five-diarrheagenic 
E. coli pathotypes. Combined vaccine candidate consisted of formalin-
killed whole cell of the main five pathotypes. Post-immunization blood 
samples were collected from mice groups weekly for six weeks. At week 
seven, mice were challenged with 106 CFU intraperitoneally and blood 
samples were collected one week after the challenge. Absorbance value 
of specific IgG antibody was measured for all seven intervals. Antibody 
absorbance values of combined vaccine candidate at selected time 
points compared to A) EAEC antigens, B) EPEC antigens, C) EIEC antigens, 
D) EHEC antigens and E) ETEC antigens. p < 0.05, ***p < 0.0001, and 
****p < 0.00001, each bar represents mean ± standard deviation.
Additional file 3: Figure S3. Evaluation of in vivo specific IgG antibody 
response measured as absorbance values elicited by unadjuvanted 
combined vaccine candidate. Balb/C mice (n = 10 mice per group) were 
immunized subcutaneously with 109 CFU of formalin killed whole cell 
antigens. Antigens belonged to the above-mentioned five-diarrheagenic 
E. coli pathotypes. Combined vaccine candidate consisted of formalin-
killed whole cell of the main five pathotypes. Post-immunization blood 
samples were collected from mice groups weekly for six weeks. At week 
seven, mice were challenged with 106 CFU intraperitoneally and blood 
samples were collected one week after the challenge. Absorbance 
values of specific IgG antibody were measured for all seven intervals. 
Antibody absorbance values of combined vaccine candidate at selected 
time points compared to A) EAEC antigens, B) EPEC antigens, C) EIEC 
antigens, D) EHEC antigens and E) ETEC antigens. (*p < 0.05, ** p < 0.001, 
***p < 0.0001, and ****p < 0.00001), each bar represents mean ± standard 
deviation.
Additional file 4: Figure S4. Evaluation of IL-6 levels elicited by alum 
adjuvanted combined vaccine candidate. Balb/C mice (n = 10 mice per 
group) were immunized subcutaneously with 109 CFU of formalin killed 
whole cell antigens. Antigens belonged to the above-mentioned five-
diarrheagenic E. coli pathotypes. Combined vaccine candidate consisted 
of formalin-killed whole cell of the main five pathotypes. Post-immuniza-
tion blood samples were collected from mice groups weekly for six weeks. 
At week seven, mice were challenged with 106 CFU intraperitoneally 
and blood samples were collected one week after the challenge. The 
concentration of IL-6 was measured for all seven intervals. IL-6 concentra-
tion of combined vaccine candidate at selected time points compared to 
A) EAEC antigens, B) EPEC antigens, C) EIEC antigens, D) EHEC antigens 
and E) ETEC antigens. *p < 0.05, ** p < 0.001, and ***p < 0.0001 each bar 
represents mean ± standard deviation.
Additional file 5: Figure S5. Evaluation of IFNγ levels elicited by alum 
adjuvanted combined vaccine candidate. Balb/C mice (n = 10 mice per 
group) were immunized subcutaneously with 109 CFU of formalin killed 
whole cell antigens. Antigens belonged to the above-mentioned five-
diarrheagenic E. coli pathotypes. Combined vaccine candidate consisted 
of formalin-killed whole cell of the main five pathotypes. Post-immuniza-
tion blood samples were collected from mice groups weekly for six weeks. 
At week seven, mice were challenged with 106 CFU intraperitoneally and 
blood samples were collected one week after the challenge. The concen-
tration of IFNγ was measured for all seven intervals. IFNγ concentration 
of combined vaccine candidate at selected time points compared to 
A) EAEC antigens, B) EPEC antigens, C) EIEC antigens, D) EHEC antigens 
and E) ETEC antigens.*p < 0.05, ** p < 0.001, and ***p < 0.0001, each bar 
represents mean ± standard deviation.
Additional file 6: Figure S6. Evaluation of IFNγ levels elicited by 
unadjuvanted combined vaccine candidate. Balb/C mice (n = 10 mice per 
group) were immunized subcutaneously with 109 CFU of formalin killed 
whole cell antigens. Antigens belonged to the above-mentioned five-
diarrheagenic E. coli pathotypes. Combined vaccine candidate consisted 
of formalin-killed whole cell of the main five pathotypes. Post-immuniza-
tion blood samples were collected from mice groups weekly for six weeks. 
At week seven, mice were challenged with 106 CFU intraperitoneally and 
blood samples were collected one week after the challenge. The concen-
tration of IFNγ was measured for all seven intervals. IFNγ concentration 
of combined vaccine candidate at selected time points compared to 
A) EAEC antigens, B) EPEC antigens, C) EIEC antigens, D) EHEC antigens 
and E) ETEC antigens. *p < 0.05, ** p < 0.001, and ***p < 0.0001, each bar 
represents mean ± standard deviation.
Additional file 7: Figure S7. Standard curve of IL-6 and IFNγ in pg/ml.
Page 17 of 18Gohar et al. BMC Res Notes  (2016) 9:80 
Acknowledgements
The authors would like to thank Dr. Mohamed Rabiae, vaccine production 
manager in VACSERA, for providing technical advice. We would like to thank 
Dr. Marwa E.A. Aly, researcher at Biotechnology Centre, Faculty of pharmacy, 
Cairo University, for providing enterotoxigenic and enteropathogenic patho-
types strains.
Competing interests
The authors declare that they have no competing interests.
Received: 31 August 2015   Accepted: 27 January 2016
References
 1. Steffen R, Castelli F, Nothdurft HD, Rombo L, Zuckerman JN. Vaccination 
against enterotoxigenic Escherichia coli, a cause of travelers’ diarrhea. J 
Travel Med. 2005;12(2):102–7.
 2. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev 
Microbiol. 2004;2(2):123–40. doi:10.1038/nrmicro818.
 3. Torres AG, Zhou X, Kaper JB. Adherence of diarrheagenic Escherichia coli 
strains to epithelial cells. Infect Immun. 2005;73(1):18–29. doi:10.1128/
IAI.73.1.18-29.2005.
 4. Okeke IN, Nataro JP. Enteroaggregative Escherichia coli. Lancet Infect Dis. 
2001;1(5):304–13. doi:10.1016/S1473-3099(01)00144-X.
 5. Harrington SM, Dudley EG, Nataro JP. Pathogenesis of enteroaggrega-
tive Escherichia coli infection. FEMS Microbiol Lett. 2006;254(1):12–8. 
doi:10.1111/j.1574-6968.2005.00005.x.
 6. Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic Escheri-
chia coli in developing countries: epidemiology, microbiology, clinical 
features, treatment, and prevention. Clin Microbiol Rev. 2005;18(3):465–
83. doi:10.1128/CMR.18.3.465-483.2005.
 7. Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 
2014;111(34):12283–7. doi:10.1073/pnas.1400472111.
 8. Plotkin SA. Vaccines, vaccination, and vaccinology. J Infect Dis. 
2003;187(9):1349–59. doi:10.1086/374419.
 9. Zhang W, Zhao M, Ruesch L, Omot A, Francis D. Prevalence of virulence 
genes in Escherichia coli strains recently isolated from young pigs with 
diarrhea in the US. Vet Microbiol. 2007;123(1–3):145–52. doi:10.1016/j.
vetmic.2007.02.018.
 10. Frydendahl K. Prevalence of serogroups and virulence genes in Escheri-
chia coli associated with postweaning diarrhoea and edema disease 
in pigs and a comparison of diagnostic approaches. Vet Microbiol. 
2002;85(2):169–82.
 11. Glenny A, Pope C, Waddington H, Wallace U. Immunological notes. XVII–
XXIV. J Pathol. 1926;29:31–40. doi:10.1002/path.1700290106.
 12. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv 
Rev. 1998;32(3):155–72.
 13. Loc NH, Yang M-S, Kim T-G. Highly expressed cholera toxin B subunit in 
the fruit of a transgenic tomato (Lycopersicon esculentum L.). Biotechnol 
Bioprocess Eng. 2011;16(3):576–80.
 14. Leal-Berumen I, Snider DP, Barajas-Lopez C, Marshall JS. Cholera toxin 
increases IL-6 synthesis and decreases TNF-alpha production by rat 
peritoneal mast cells. J Immunol. 1996;156(1):316–21.
 15. Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induc-
tion with antigen conjugated to cholera toxin B subunit generates both 
Foxp3 + CD25 + and Foxp3-CD25-CD4 + regulatory T cells. J Immunol. 
2006;177(11):7634–44.
 16. Tarkowski A, Sun JB, Holmdahl R, Holmgren J, Czerkin-
sky C. Treatment of experimental autoimmune arthritis 
by nasal administration of a type II collagen-cholera tox-
oid conjugate vaccine. Arthritis Rheum. 1999;42(8):1628–34. 
doi:10.1002/1529-0131(199908)42:8<1628:AID-ANR10>3.0.CO;2-T.
 17. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, 
regional, and national causes of child mortality: an updated sys-
tematic analysis for 2010 with time trends since 2000. Lancet. 
2012;379(9832):2151–61.
 18. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. 
Global, regional, and national causes of child mortality in 2008: a 
systematic analysis. Lancet. 2010;375(9730):1969–87. doi:10.1016/
S0140-6736(10)60549-1.
 19. Zhang W, Sack DA. Progress and hurdles in the development of vaccines 
against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines. 
2012;11(6):677–94. doi:10.1586/erv.12.37.
 20. Horne C, Vallance BA, Deng W, Finlay BB. Current progress in enter-
opathogenic and enterohemorrhagic Escherichia coli vaccines. Expert Rev 
Vaccines. 2002;1(4):483–93. doi:10.1586/14760584.1.4.483.
 21. Svennerholm AM, Lundgren A. Recent progress toward an enterotoxi-
genic Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(4):495–507. 
doi:10.1586/erv.12.12.
 22. Dodd D. Benefits of combination vaccines: effective vaccination on a 
simplified schedule. Am J Manag Care. 2003;9(1 Suppl):S6–12.
 23. Lopez-Gigosos RM, Plaza E, Diez-Diaz RM, Calvo MJ. Vaccination strategies 
to combat an infectious globe: oral cholera vaccines. J Glob Infect Dis. 
2011;3(1):56–62. doi:10.4103/0974-777X.77297.
 24. Boll EJ, McCormick BA. A new understanding of enteroaggrega-
tive Escherichia coli as an inflammatory pathogen. Cell Adh Migr. 
2012;6(5):413–8. doi:10.4161/cam.21241.
 25. Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. 
Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect 
Dis. 2001;183(3):435–43.
 26. Ishikawa S, Kawahara K, Kagami Y, Isshiki Y, Kaneko A, Matsui H, et al. 
Protection against Shiga toxin 1 challenge by immunization of mice with 
purified mutant Shiga toxin 1. Infect Immun. 2003;71(6):3235–9.
 27. Marcato P, Griener TP, Mulvey GL, Armstrong GD. Recombinant Shiga 
toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects 
mice from Shigatoxemia. Infect Immun. 2005;73(10):6523–9.
 28. Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA. Serological 
response of Shiga toxin-producing Escherichia coli type III secreted 
proteins in sera from vaccinated rabbits, naturally infected cattle, and 
humans. Clin Vaccine Immunol. 2011;18(7):1052–7.
 29. Liu J, Sun Y, Feng S, Zhu L, Guo X, Qi C. Towards an attenuated entero-
hemorrhagic Escherichia coli O157: h7 vaccine characterized by a 
deleted ler gene and containing apathogenic Shiga toxins. Vaccine. 
2009;27(43):5929–35.
 30. Torres AG. Intestinal pathogenic Escherichia coli. In: Barrett ADT, Stanberry 
LR, editors. Vaccines for biodefense and emerging and neglected dis-
eases. London: Academic Press; 2009. p. 1013–29.
 31. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr, et al. 
Introductory evaluation of an oral, killed whole cell enterotoxigenic 
Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. 
Pediatr Infect Dis J. 2002;21(4):322–30.
 32. Savarino SJ, Hall ER, Bassily S, Brown FM, Youssef F, Wierzba TF, et al. Oral, 
inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin 
B subunit vaccine: results of the initial evaluation in children. J Infect Dis. 
1999;179(1):107–14. doi:10.1086/314543 (PRIDE Study Group).
 33. Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immuno-
genicity by limiting susceptibility to lysosomal proteolysis. J Exp Med. 
2006;203(9):2049–55. doi:10.1084/jem.20052442.
 34. Marrack P, McKee AS, Munks MW. Towards an understanding of the 
adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–93. 
doi:10.1038/nri2510.
 35. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. 
Immunol Cell Biol. 2004;82(5):488–96.
 36. Anjuere F, Luci C, Lebens M, Rousseau DB, Hervouet C, Milon GV, 
et al. In vivo adjuvant-induced mobilization and maturation of gut 
dendritic cells after oral administration of cholera toxin. J Immunol. 
2004;173(8):5103–11.
 37. Gagliardi MC, Sallusto F, Marinaro M, Vendetti S, Riccomi A, De Magistris 
MT. Effects of the adjuvant cholera toxin on dendritic cells: stimula-
tory and inhibitory signals that result in the amplification of immune 
responses. Int J Med Microbiol. 2001;291(6):571–5.
 38. Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP. Parenteral 
adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for 
immunization of mice against gastric Helicobacter pylori infection. Infect 
Immun. 2000;68(5):2775–82.
 39. Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, 
et al. Protective effect of nasal immunization of influenza virus 
hemagglutinin with recombinant cholera toxin B subunit as a 
Page 18 of 18Gohar et al. BMC Res Notes  (2016) 9:80 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
mucosal adjuvant in mice. Microbiol Immunol. 2008;52(2):55–63. 
doi:10.1111/j.1348-0421.2008.00010.x.
 40. Maeyama J, Isaka M, Yasuda Y, Matano K, Morokuma K, Ohkuma K, et al. 
Effects of recombinant cholera toxin b subunit (rCTB) on cellular immune 
responses: enhancement of delayed-type hypersensitivity following intra-
nasal co-administration of Mycobacterium bovis-BCG with rCTB. Microbiol 
Immunol. 2004;48(6):457–63.
 41. Isaka M, Komiya T, Takahashi M, Yasuda Y, Taniguchi T, Zhao Y, et al. 
Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant 
enhances induction of diphtheria and tetanus antitoxin antibodies in 
mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) 
combination vaccine. Vaccine. 2004;22(23–24):3061–8. doi:10.1016/j.
vaccine.2004.02.019.
 42. Yasuda Y, Isaka M, Taniguchi T, Zhao Y, Matano K, Matsui H, et al. Frequent 
nasal administrations of recombinant cholera toxin B subunit (rCTB)-con-
taining tetanus and diphtheria toxoid vaccines induced antigen-specific 
serum and mucosal immune responses in the presence of anti-rCTB 
antibodies. Vaccine. 2003;21(21–22):2954–63.
 43. Isaka M, Yasuda Y, Taniguchi T, Kozuka S, Matano K, Maeyama J, et al. 
Mucosal and systemic antibody responses against an acellular pertussis 
vaccine in mice after intranasal co-administration with recombinant 
cholera toxin B subunit as an adjuvant. Vaccine. 2003;21(11–12):1165–73.
 44. Maeyama J, Isaka M, Yasuda Y, Matano K, Kozuka S, Taniguchi T, et al. 
Cytokine responses to recombinant cholera toxin B subunit pro-
duced by Bacillus brevis as a mucosal adjuvant. Microbiol Immunol. 
2001;45(2):111–7.
 45. George-Chandy A, Eriksson K, Lebens M, Nordstrom I, Schon E, Holmgren 
J. Cholera toxin B subunit as a carrier molecule promotes antigen presen-
tation and increases CD40 and CD86 expression on antigen-presenting 
cells. Infect Immun. 2001;69(9):5716–25.
 46. Aramaki Y, Suda H, Tsuchiya S. Interferon gamma inductive effect of 
liposomes as an immunoadjuvant. Vaccine. 1995;13(18):1809–14.
 47. Boll EJ, Struve C, Sander A, Demma Z, Krogfelt KA, McCormick BA. 
Enteroaggregative Escherichia coli promotes transepithelial migration of 
neutrophils through a conserved 12-lipoxygenase pathway. Cell Micro-
biol. 2012;14(1):120–32. doi:10.1111/j.1462-5822.2011.01706.x.
 48. Ramos CD, Fernandes KS, Canetti C, Teixeira MM, Silva JS, Cunha FQ. Neu-
trophil recruitment in immunized mice depends on MIP-2 inducing the 
sequential release of MIP-1alpha, TNF-alpha and LTB(4). Eur J Immunol. 
2006;36(8):2025–34. doi:10.1002/eji.200636057.
 49. Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW. Emerging 
mechanisms of neutrophil recruitment across endothelium. Trends 
Immunol. 2011;32(10):461–9. doi:10.1016/j.it.2011.06.009.
 50. Rose R, Moon HW. Elicitation of enteroluminal neutrophils by enterotoxi-
genic and nonenterotoxigenic strains of Escherichia coli in swine. Infect 
Immun. 1985;48(3):818–23.
 51. Aly MEA, Essam TM, Amin MA. Involvement of virulence genes and 
antibiotic resistance in clinical and food borne diarrheagenic Escherichia 
coli isolates from Egypt. World J Med Sci. 2012;7(4):276–84.
 52. Aly ME, Essam TM, Amin MA. Antibiotic resistance profile of E. coli strains 
isolated from clinical specimens and food samples in Egypt. Int J Micro-
biol Res. 2012;3(3):176–82.
 53. Lim SY, Bauermeister A, Kjonaas RA, Ghosh SK. Phytol-based novel adju-
vants in vaccine formulation: 2. Assessment of efficacy in the induction 
of protective immune responses to lethal bacterial infections in mice. J 
Immune Based Ther Vaccines. 2006;4:5. doi:10.1186/1476-8518-4-5.
 54. WHO. General requirements for the sterility of biological substances 
Journal. 1973;2015(Issue):Revised 1973, TRS No 530, Annex 4.
 55. Burrell LS, Lindblad EB, White JL, Hem SL. Stability of aluminium-contain-
ing adjuvants to autoclaving. Vaccine. 1999;17(20–21):2599–603.
 56. Lindblad EB. Aluminium adjuvants–in retrospect and prospect. Vaccine. 
2004;22(27–28):3658–68. doi:10.1016/j.vaccine.2004.03.032.
 57. Melikova EN, Lesnjak SV. International reference preparations of typhoid 
vaccine. Potency assay by the active mouse protection test with three dif-
ferent routes of immunization. Bull World Health Organ. 1967;37(4):575–9.
 58. Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf 
MK, et al. Safety and immunogenicity of a prototype enterotoxigenic 
Escherichia coli vaccine administered transcutaneously. Infect Immun. 
2002;70(4):1874–80.
 59. Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immu-
nogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. 
Vaccine. 1998;16(2–3):255–60.
 60. Svennerholm AM, Holmgren J, Black R, Levine M, Merson M. Sero-
logic differentiation between antitoxin responses to infection with 
Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis. 
1983;147(3):514–22.
